The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2019 | NGS: a valuable tool for elucidating the genetic landscape of AML
Torsten Haferlach, MD, of Munich Leukemia Laboratory, Munich, Germany, discusses how next-generation sequencing (NGS) can significantly facilitate the uncovering of genetic mutations associated with acute myeloid leukemia (AML). Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Prof. Haferlach reports that NGS can enable scientists to gain important information for diagnosis, prognostication and measurable residual disease (MRD) in the context of AML.
